Transgenic Mouse Senescent Cell Clearance via p16INK4a Promoter
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively target and remove senescent cells, which accumulate with age and contribute to age-related disorders, without affecting non-senescent cells.
Innovation Solution
Transgenic non-human animals are developed with a transgene that selectively induces apoptosis in senescent cells using a compound like AP20187, minimizing apoptosis in non-senescent cells, allowing for controlled clearance of p16Ink4a-positive senescent cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If current methods are used to remove senescent cells, then senescent cell accumulation is addressed, but non-senescent cells are also affected causing harm
Solution Approach 1:
The patent applies local quality by using a promoter that is specifically active in senescent cells (p16Ink4a promoter) to drive expression of the pro-apoptotic polypeptide. This ensures that the apoptotic effect is localized only to senescent cells which express the promoter, while non-senescent cells that do not express the promoter remain unaffected. The selective expression pattern creates a spatial and cellular specificity that resolves the contradiction between removing harmful senescent cells and preserving healthy non-senescent cells.
Solution Approach 2:
The patent uses an intermediary approach by introducing a transgenic system with a conditional pro-apoptotic polypeptide that requires both promoter activation and compound administration to function. The compound acts as an intermediary trigger that activates the apoptotic pathway only when present, providing temporal control. This dual-control mechanism (promoter-specific expression plus compound-induced activation) ensures selective removal of senescent cells while protecting non-senescent cells from unintended apoptosis.
2Reliability
If a transgene is designed to induce apoptosis in senescent cells, then selective clearance is achieved, but complexity of the genetic system increases
Solution Approach 1:
The patent employs universality by using a well-established promoter (p16Ink4a) that is already known to be senescent-cell-specific, and a validated pro-apoptotic polypeptide sequence. These universal, well-characterized components allow the system to achieve reliable selective clearance without requiring de novo design of complex regulatory elements. The use of standardized genetic parts that have been previously validated in other contexts reduces the overall complexity while maintaining high reliability in the intended application.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach delays or reduces the likelihood of age-related disorders and maximizes healthy lifespan by selectively removing senescent cells while sparing non-senescent cells, as demonstrated in transgenic mouse models.
Implementation Method 1
a nucleic acid sequence encoding a polypeptide having the ability to kill a cell or facilitate the killing of a cell when the transgenic mouse is administered a compound
Implementation Method 2
The polypeptide can be an FKBP-caspase 8 fusion polypeptide
Data Source
AI summary
This document provides a transgenic mouse for studying the role of senescent cells in an age-related phenotype. A recombinant polypeptide is expressed in senescent cells under control of a p16INK4a promoter. The polypeptide can be triggered to directly induce cell death in senescent cells. As a result, progression of one or more age-related phenotypes is delayed in the mouse. An example is the INK-ATTAC mouse which also expresses a marker polypeptide in senescent cells.